Case Report: FIA plus venetoclax in a patient on hemodialysis
Jacob E. Herstein, Kayleigh R. Marx, J. Michael Savoy, Wei Ying Jen, Musa Yilmaz, Nicholas J. Short, Ghayas C. Issa, Farhad Ravandi, Tapan M. Kadia, Naval G. Daver, Courtney D. DiNardo
TL;DR
A patient with kidney failure and leukemia successfully responded to a specific chemotherapy regimen.
Contribution
This case report demonstrates the successful use of FIA plus venetoclax in a hemodialysis-dependent AML patient.
Findings
A 65-year-old female on hemodialysis achieved complete remission with FIA plus venetoclax for AML.
The regimen was safely administered despite challenges in patients with end-stage renal disease.
Interdisciplinary coordination was essential for managing pharmacological and logistical barriers.
Abstract
The safe and effective delivery of curative cytotoxic chemotherapy for acute myeloid leukemia (AML) in patients receiving intermittent hemodialysis (IHD) for end-stage renal disease (ESRD) remains a clinical challenge; pharmacological and logistical barriers necessitate close interdisciplinary coordination. In this case, we report a 65-year-old female patient with chronic ESRD on IHD and newly diagnosed AML who achieved complete remission (CR) after treatment with fludarabine, idarubicin, and cytarabine plus venetoclax (i.e., FIA + venetoclax).
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAcute Myeloid Leukemia Research · Chemotherapy-induced organ toxicity mitigation · Chronic Myeloid Leukemia Treatments